Latest Period
Q1 2026
Security Snapshot
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) Institutional Ownership
CUSIP: 45719W205
13F Institutional Holders and Ownership History from Q1 2023 to Q1 2026
Institutions Reporting
104
Shares (Excl. Options)
115,144,233
Price
$1.68
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value
- Symbol
- IKT on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 115,144,233
- Total 13F value
- $193,410,980
- Portfolio coverage rank
- 0%
- Share change
- +7,605,782
- Value change
- +$11,923,862
- Number of holders
- 104
- Shares outstanding
- 140,000,283
- SEC-reported price per share
- $1.70
- Insider filing price
- $1.70
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value is tracked under CUSIP 45719W205.
- 104 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 73 to 104 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $218,151,569 to $193,410,980.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 104 institutions filings for Q1 2026.
Security key
45719W205
Latest holder period
Q1 2026
13F holders
104
13D/G owners
8
CIK / CUSIP context first
Open Q1 2026 holders
IKT full holder history
Inhibikase Therapeutics, Inc. SEC filings
Inhibikase Therapeutics, Inc. company facts
Inhibikase Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45719W205:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
IKT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | $25,439,441 | 14,054,940 | Commodore Capital LP | 31 Mar 2026 | |||
| ADAR1 Capital Management, LLC | 9.9% | 0% | $25,086,651 | +$2,113,430 | 13,860,028 | +9.2% | ADAR1 Capital Management, LLC | 31 Mar 2026 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 11% | -26% | $26,037,930 | +$4,137,930 | 13,018,965 | +19% | Sands Capital Life Sciences Pulse Fund II, L.P. | 31 Dec 2025 |
| PERCEPTIVE ADVISORS LLC | 8.9% | -11% | $22,870,934 | -$327,190 | 12,635,875 | -1.4% | Perceptive Advisors LLC | 31 Mar 2026 |
| Fairmount Funds Management LLC | 9.9% | 0% | $24,922,202 | +$10,885,052 | 12,461,101 | +78% | Fairmount Funds Management LLC | 31 Dec 2025 |
| Trails Edge Capital Partners, LP | 6.1% | +20% | $14,583,794 | +$3,460,986 | 8,057,345 | +31% | Trails Edge Capital Partners, LP | 31 Mar 2026 |
| Nantahala Capital Management, LLC | 5.7% | -23% | $14,075,832 | +$3,478,584 | 7,037,916 | +33% | Nantahala Capital Management, LLC | 31 Dec 2025 |
| ARMISTICE CAPITAL, LLC | 5% | $7,975,554 | 3,529,006 | Armistice Capital, LLC | 31 Dec 2024 |
As of 31 Mar 2026, 104 institutional investors reported holding 115,144,233 shares of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT). This represents 82% of the company’s total 140,000,283 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
78%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Sands Capital Alternatives, LLC | 9.3% | 13,018,965 | 0% | 5.2% | $21,871,861 |
| Soleus Capital Management, L.P. | 7.8% | 10,875,000 | 0% | 0.74% | $18,270,000 |
| Fairmount Funds Management LLC | 6.2% | 8,625,000 | 0% | 1% | $14,490,000 |
| Trails Edge Capital Partners, LP | 5.8% | 8,057,345 | +30% | 3.2% | $13,536,340 |
| ADAR1 Capital Management, LLC | 4.7% | 6,606,572 | -18% | 0.67% | $11,099,041 |
| BlackRock, Inc. | 4.5% | 6,303,433 | +91% | 0% | $10,589,768 |
| Blackstone Inc. | 4.2% | 5,938,276 | 0% | 0.04% | $9,976,304 |
| Siren, L.L.C. | 4.2% | 5,850,000 | 0% | 0.27% | $9,828,000 |
| Commodore Capital LP | 3.9% | 5,397,488 | 0% | 0.52% | $9,067,780 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 4,450,665 | 0% | 0% | $7,477,117 |
| Saturn V Capital Management LP | 2.8% | 3,863,445 | +0.17% | 1.2% | $6,490,588 |
| Kalehua Capital Management LLC | 2.7% | 3,821,890 | +118% | 4.5% | $6,420,775 |
| Spruce Street Capital LP | 2.6% | 3,581,603 | 0% | 1.4% | $6,017,093 |
| Squadron Capital Management LLC | 2.5% | 3,500,000 | -17% | 2.4% | $5,880,000 |
| MILLENNIUM MANAGEMENT LLC | 2.1% | 2,928,077 | +1624% | 0% | $4,919,169 |
| Nantahala Capital Management, LLC | 1.9% | 2,701,863 | -31% | 0.28% | $4,539,130 |
| PERCEPTIVE ADVISORS LLC | 1.7% | 2,315,000 | -57% | 0.08% | $3,889,200 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 2,170,186 | +92% | 0% | $3,646,792 |
| STATE STREET CORP | 1.2% | 1,685,816 | +204% | 0% | $2,832,171 |
| SummitTX Capital, L.P. | 1.1% | 1,524,536 | 0.08% | $2,561,220 | |
| Integral Health Asset Management, LLC | 0.96% | 1,350,000 | -23% | 0.12% | $2,268,000 |
| Ally Bridge Group (NY) LLC | 0.95% | 1,325,000 | 2.2% | $2,226,000 | |
| CITADEL ADVISORS LLC | 0.79% | 1,102,585 | -11% | 0% | $1,852,343 |
| Stonepine Capital Management, LLC | 0.68% | 957,202 | -59% | 1.4% | $1,608,099 |
| TWO SIGMA INVESTMENTS, LP | 0.61% | 847,611 | 0% | $1,423,986 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
13
Latest
Q1 2026
Rows shown
1-13 of 13
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 115,144,233 | $193,410,980 | +$11,923,862 | $1.68 | 104 |
| 2025 Q4 | 106,415,262 | $218,151,569 | +$72,128,708 | $2.05 | 73 |
| 2025 Q3 | 54,964,771 | $89,043,214 | +$712,913 | $1.62 | 53 |
| 2025 Q2 | 54,512,097 | $106,299,597 | +$5,482,917 | $1.95 | 48 |
| 2025 Q1 | 51,462,756 | $112,702,942 | +$3,027,389 | $2.19 | 47 |
| 2024 Q4 | 50,059,308 | $162,691,896 | +$161,164,562 | $3.25 | 31 |
| 2024 Q3 | 860,232 | $1,118,330 | +$30,199 | $1.30 | 11 |
| 2024 Q2 | 836,496 | $1,021,038 | +$723,392 | $1.21 | 12 |
| 2024 Q1 | 205,558 | $443,782 | -$62,190 | $2.16 | 12 |
| 2023 Q4 | 235,004 | $298,925 | -$271,105 | $1.27 | 11 |
| 2023 Q3 | 429,662 | $597,627 | -$496,803 | $1.39 | 13 |
| 2023 Q2 | 747,138 | $2,693,647 | +$2,394,678 | $3.61 | 14 |
| 2023 Q1 | 82,817 | $54,460 | +$54,460 | $0.66 | 1 |